Vliyanie terapii polovymi gormonami na sostoyanie molochnykh zhelez u zhenshchin s defitsitom androgenov i fibrozno-kistoznoy bolezn'yu
- Authors: Apetov SS1, Kalinchenko SY.1, Agafonova AV1, Sotnikova LS1
-
Affiliations:
- Issue: Vol 14, No 3 (2012)
- Pages: 58-61
- Section: Articles
- URL: https://gynecology.orscience.ru/2079-5831/article/view/33316
- ID: 33316
Cite item
Full Text
Abstract
References
- Сметник В.П. Красота зрелого возраста. Status Praesents, 2011.
- Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: a systematic review. Obes Rev 2003; 4 (3): 157-73.
- Hulca BS, Moorman PG. Reprint of Breast cancer: hormones and other risk factors. Maturitas 2008; 61: 203-13.
- Fournier F. Clavel-Chapelon. Unicual risks for breast cancer associated with different hormone replacement therapies results from the E3N cohort study. Breast Cancer Res Treat 2008; 107 (1): 103-11.
- Fabre A, Fournier A, Mesrine S et al. Oral progestagens before menopause and breast cancer risk. Br J Cancer 2007; 96 (5): 841-4.
- Alfred O, Muecka, Seegera H, Kai-J. Use of dydrogesterone in hormone replacement therapy. Maturitas 2009: 65S, S51-S60.
- Радзинский В.Е., Калинченко С.Ю., Апетов С.С. Терапия андрогенами в гинекологической практике. Вестн. РУДН. 2010; 6: 196-204.
- Braunstein GD, Sundwall DA, Kate M et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: randomized placebo-controlled trial. Arch Intern Med 2005; 165: 1582-9.
- Buster JE, Kingsberg SA, Brown C et al. Testosterone patch for low sexual desire in surgically menopausal women: A randomized trial. Obstet Gynecol 2005; 105: 944-52.
- Davis SR, Bouchard C, Kroll R et al. The effect of a testosterone transdermal system on hypoactive sexual desire disorder in postmenopausal women not receiving systemic estrogen therapy, the aphrodite study. 82nd Annual Meeting of the Endocrine Society; Boston USA, 2006.
- Somboonporn W, Davis SR. Postmenopausal testosterone therapy and breast cancer risk. Maturitas 2004; 49: 267-75.
- Labrie F, Luu-The V, Labrie C et al. Endocrine and intracrine sources of androgens in women: Inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003; 24: 152-82.
- Gammon MD, Thompson WD. Polycystic ovaries and the risk of breast cancer. Am J Epidemiol 1991; 134: 818-24.
- Burgess HE, Shousha S. An immunohistochemical study of the long-term effects of androgen administration on female-to-male transsexual breast: A comparison with normal female breast and male breast showing gynaecomastia. J Pathol 1993; 170: 37-43.
- Dimitrakakis C, Jones RA, Liu A, Bondy CA. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause 2004; 11: 531-5.
- Сотникова Л.С. Мастопатия. Новые аспекты в лечении. 2011; с. 6-14.
- Радзинский В.Е, Калинченко С.Ю., Апетов С.С. Синдром дефицита андрогенов у женщин. Вестн. РУДН. 2010; 6: 266-76.
- Bachmann GA, Bancroft J, Braunstein G et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification and assessment. Fertil Steril 2002; 77: 660-5.
- Guay A, Munarriz R, Jacobson J et al. Serum androgen levels in healthy premenopausal women with and without sexual dysfunction: Part A. Serum androgen levels in women aged 20-49 years with no complaints of sexual dysfunction, kit. J Impot Res 2004; 16: 112-20.
- Davison SL, Bell R, Donath S et al. Androgen levels in adult females: Changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005; 90: 3847-53.
- Zumoff B, Strain GW, Miller LK, Rosner W. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab 1995; 80: 1429-30.
- Singh AB, Lee ML, Sinha-Hikim I et al. Pharmacokinetics of a testosterone gel in healthy postmenopausal women. J Clin Endocrinol Metab 2006; 91: 136-44.
- Braunstein GD. The Endocrine Society Clinical Practice Guideline and The North American Menopause Society position statement on androgen therapy in women: Another one of Yogi's forks. J Clin Endocrinol Metab 2007; 92: 4091-3.
- Hofling M, Carlstrom K, Svane G et al. Different effects 'of tibolone and continuous combined estrogen plus progestogen hormone therapy on sex hormone binding globulin and free testosterone levels an association with mammographic density. Gynecol Endocrinol 2005; 20: 110-5.
- Hofling M, Hirschberg AL, Skoog L et al. Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause 2007; 14: 183-90.
- Burger HG. Should testosterone be added to estrogen-progestin therapy for breast protection? Menopause 2007; 14: 159-62.